Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026
Novo Nordisk has unveiled compelling Phase 3 clinical data for its investigational therapy CagriSema, demonstrating significant reductions in both HbA1c levels and body weight across multiple studies in the REIMAGINE clinical development program. Presented during a late-breaking symposium at the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans, the findings reinforce the potential of CagriSema as a next-generation treatment option for people living with type 2 diabetes (T2D). The once-weekly therapy combines cagrilintide, a long-acting amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist, creating a dual-mechanism approach designed to improve glycemic control while delivering substantial weight reduction.
Phase 3 REIMAGINE Program Meets Key Clinical Endpoints
The REIMAGINE program consists of a series of global Phase 3 studies evaluating CagriSema in adults with type 2 diabetes at different stages of disease progression. Across REIMAGINE 1, REIMAGINE 2, and REIMAGINE 3, the investigational therapy consistently achieved its primary endpoint of significant HbA1c reduction while also meeting confirmatory secondary endpoints related to body weight loss.
In REIMAGINE 1, adults with inadequately controlled type 2 diabetes receiving CagriSema 2.4 mg/2.4 mg experienced a 1.8% reduction in HbA1c and a remarkable 13.8% decrease in body weight, substantially outperforming placebo. The study highlighted the effectiveness of combining amylin and GLP-1 pathways to address multiple aspects of diabetes management.
REIMAGINE 2 enrolled more than 2,700 participants and compared CagriSema against semaglutide and cagrilintide monotherapies. Results showed that CagriSema 2.4 mg/2.4 mg achieved a 1.91% reduction in HbA1c and a 14.2% reduction in body weight, demonstrating superiority over semaglutide alone and reinforcing the clinical value of the combination approach.
Advertisement
Dual Hormonal Mechanism Advances Diabetes Management
The success of CagriSema is rooted in its innovative combination of two complementary hormones. Amylin, naturally co-secreted with insulin, plays a role in appetite regulation, glycemic control, and body weight management, while GLP-1 receptor agonists have become a cornerstone of modern diabetes therapy. By integrating both mechanisms into a single once-weekly injection, Novo Nordisk aims to provide a more comprehensive treatment strategy for individuals struggling to achieve glycemic targets and meaningful weight reduction.
Experts involved in the REIMAGINE program emphasized that the combination therapy addresses multiple metabolic pathways simultaneously, potentially offering a differentiated treatment option for patients requiring enhanced glucose control and sustained weight management. The data also support growing scientific interest in amylin-based therapies as a complement to established GLP-1 treatments.
Strong Results Extend to Insulin-Treated Patients
The REIMAGINE 3 study further demonstrated the broad applicability of CagriSema among patients already receiving basal insulin therapy. Participants treated with CagriSema 2.4 mg/2.4 mg achieved a 2.33% reduction in HbA1c and a 12.0% decrease in body weight, highlighting the therapy’s ability to deliver clinically meaningful outcomes even in more advanced stages of type 2 diabetes.
Safety findings across the program were generally consistent with the known profile of incretin-based therapies. Gastrointestinal adverse events were the most commonly reported side effects, with discontinuation rates remaining relatively low across treatment groups. These findings provide additional confidence in the therapy’s benefit-risk profile as Novo Nordisk continues advancing its regulatory strategy.
With the REIMAGINE program successfully meeting key endpoints and demonstrating robust efficacy across diverse patient populations, CagriSema is emerging as a potential first-in-class amylin and GLP-1 combination therapy capable of transforming diabetes care through superior blood glucose control and substantial weight reduction. The results further strengthen Novo Nordisk’s leadership in metabolic disease innovation and highlight the growing importance of combination therapies in the future treatment landscape for type 2 diabetes.
Source: Novo Nordisk press release
